Ashwagandha and EGCG
Supplement–drug interaction evidence from the TruthStack database.
| Severity | HIGH |
|---|---|
| Evidence Tier | Moderate |
| Interaction Type | SAFETY CONCERN |
| Mechanism | PHARMACODYNAMIC |
| Last Reviewed | 2026-02-15 |
Summary
Both have documented idiosyncratic hepatotoxicity; synergistic liver load especially fasted. Consider taking both with food; stay moderate dose; monitor liver markers
Higher-Concern Contexts
This interaction may be of particular concern in the following contexts:
- hepatic impairment
CYP Enzyme Profiles
Published CYP enzyme data for compounds in this interaction:
EGCG: CYP1A2 substrate (moderate), CYP3A4 inhibitor (weak)
Shared Pharmacodynamic Endpoints
Both compounds influence the same physiological endpoints in the same direction:
| Endpoint | Direction | Ashwagandha | EGCG |
|---|---|---|---|
| BLOOD GLUCOSE | DECREASE | MODERATE | WEAK |
Cumulative effect on shared endpoints may exceed individual compound profiles. This is relevant to discussion with a prescribing clinician.
API Reference
GET https://api.truthstack.co/v1/check?c1=Ashwagandha&c2=EGCG
Open, unauthenticated. Returns JSON. Developer documentation
Related Interactions
What this page is and is not. TruthStack is an informational reference database that describes published pharmacological findings. It does not provide medical advice, diagnosis, or treatment recommendations. The information on this page reflects flags in our database and should not replace consultation with a qualified healthcare provider. Always discuss supplement-drug combinations with your prescriber or pharmacist.